An Overview of the Investigational HIV-1 Maturation Inhibitor GSK3739937 (VH3739937)

I. Introduction to GSK3739937

A. Overview of GSK3739937 (VH3739937)

GSK3739937, also identified in scientific literature and development programs as VH3739937 or by the internal research code VH-937, is an investigational small molecule compound.[1] It has been developed primarily for its potential therapeutic application in the management of Human Immunodeficiency Virus Type 1 (HIV-1) infection.[1] The compound is structurally related to GSK3640254, an earlier-generation HIV-1 maturation inhibitor.[5] The consistent use of dual nomenclature, GSK3739937 and VH3739937, across research publications and trial registries is noteworthy, with "VH" likely indicating the involvement of ViiV Healthcare in its development. This is a common practice in pharmaceutical development where internal research codes (e.g., VH-937) and corporate identifiers (e.g., GSK3739937) may be used concurrently. Clarification of this nomenclature is important for accurately tracking the compound's progress through various stages of research and development.

B. Chemical Nature and Drug Class (HIV-1 Maturation Inhibitor)